2025年中国SIRNA药物行业产业链、市场规模、在研数量、应用结构、竞争格局及发展趋势研判：行业开发正处于快速发展期，发展空间巨大[图]

Core Insights - The siRNA drug market is experiencing rapid growth, with the number of drugs in development reaching 289 in 2023, a growth rate of 103.52% since 2017, and projected to increase to 338 in 2024 [1][6] - The global siRNA drug market is expected to grow to $2.4 billion in 2024, with the U.S. market accounting for $1.3 billion, and is projected to reach $3.1 billion in 2025 [1][6] - siRNA drugs are primarily used for treating genetic and metabolic diseases, with ongoing research expanding their application to oncology, cardiovascular, neurological, and immune system diseases [1][6] siRNA Drug Industry Definition - siRNA (small interfering RNA) consists of double-stranded RNA fragments containing 19-23 base pairs, which target disease tissues for gene silencing through RNA interference (RNAi) mechanisms [2] Current Development Status - The siRNA drug market is characterized by significant potential in the biopharmaceutical field, particularly in oncology, with 17.9% of drugs targeting tumors [6] - The market is projected to see a substantial increase in both the number of drugs in development and market size, indicating a robust growth trajectory [1][6] Industry Chain - The siRNA drug industry chain includes upstream suppliers of high-purity RNA monomers and nucleotides, midstream drug development and production, and downstream applications in hospitals and medical institutions [7] Competitive Landscape - Since the first siRNA drug was approved in 2018, the market has seen significant clinical and commercial validation, with seven siRNA products approved globally by 2025 [9][10] - Domestic siRNA development is rapidly advancing, with several companies emerging as leaders in the field, such as Regeron and Saint Pharma [11] Industry Development Trends - siRNA drugs are gaining attention due to their unique mechanism and potential clinical efficacy in treating malignancies and genetic diseases [12] - The industry is expected to benefit from the participation of large pharmaceutical companies, enhancing creativity and competitiveness within the sector [12]